NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

AVR-RD-01:到2030年考慮新藥和市場預測

AVR RD 01 - Emerging Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 959696
出版日期 按訂單生產 內容資訊 英文 50 Pages
商品交期: 10個工作天內
價格
AVR-RD-01:到2030年考慮新藥和市場預測 AVR RD 01 - Emerging Drug Insight and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 50 Pages
簡介

AVROBIO正在研究和開髮用於法布裡氏病的基因治療劑AVR-RD-01,目前正在進行兩項臨床試驗。在加拿大的I期研究中,對五名受試者進行了給藥,在澳大利亞,美國和加拿大的II期臨床研究中,對四名受試者進行了給藥。

本報告調查了七個主要國家(包括美國,德國,法國,意大利,西班牙,英國和日本)的AVR-RD-01市場,並提出了2030年的前景。市場評估,SWOT分析,競爭對手概況,其他新方法等等。

調查範圍

  • 全面的產品概述,包括產品描述,作用機理,劑量和給藥方法,研發活動
  • 開發活動的詳細信息,例如法規批准程序的里程碑
  • 美國,歐洲和日本的藥物研發詳細信息
  • 包括AVR-RD-01到期日期在內的專利信息
  • 到2030年AVR-RD-01的銷售預測
  • 有關晚期法布裡氏病新治療劑的綜合信息(第三階段)
  • 分析師的考慮和SWOT分析

報告重點

  • 法布裡(Fabry)的疾病療法由於全球範圍內的持續研發和醫療費用的增加而發生了巨大變化,並且市場的擴大有望增加進入市場的製藥公司的數量。
  • 公司和研究人員正在尋找機會,以增強AVR-RD-01的優越性。當前正在開發的治療方法集中於治療/改善疾病的新方法。
  • 與AVR-RD-01競爭的新競爭產品已經出現,並有望在不久的將來對市場產生重大影響。

本報告解決的主要問題

  • 哪個公司在開發AVR-RD-01?
  • AVR-RD-01的開發中使用了什麼技術?
  • AVR-RD-01的產品類型,給藥途徑和作用機理是什麼?
  • 臨床試驗的狀態和完成日期是什麼時候?
  • 與AVR-RD-01的開發有關的合作,合併,收購和許可等主要運動是什麼?
  • AVR-RD-01的主要規格是什麼?
  • AVR-RD-01的預測市場方案是什麼?
  • AVR-RD-01的過去動向和未來展望是什麼?
  • 您對AVR-RD-01在美國,德國,法國,意大利,西班牙,英國和日本的銷售預測是什麼?
  • 還有哪些其他新興產品可用?這些產品如何競爭?
  • 在開發後期,目前有哪些新的治療劑?

目錄

第1章藥物概述

  • 產品詳細信息
  • 作用機理
  • 藥物和管理
  • 研發活動
    • 臨床發展
    • 安全性和有效性
  • 其他發展活動

第2章市場評估

  • 7個主要國家的市場分析
  • 美國市場
  • 德國市場
  • 法國市場
  • 意大利市場
  • 西班牙市場
  • 英國市場
  • 日本市場

第3章SWOT分析

第4章分析師的觀點

第5章市場競爭

第6章其他新補救措施

第7章附錄

第8章報表購買選項

目錄
Product Code: DIDM0047

"AVR RD 01 - Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Fabry Disease in 7 Major Markets. A detailed picture of the AVR RD 01 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

AVROBIO's investigational gene therapy for Fabry disease is currently being studied in two clinical trials. An investigator-sponsored Phase 1 trial in Canada is fully enrolled, with five patients dosed. The trial is initiated: FAB-201, the Phase 2 trial, has dosed four treatment-naive patients through December 2019 and continues to enroll in Australia, the U.S. and Canada.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around AVR RD 01.
  • The report contains forecasted sales for AVR RD 01 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Fabry Disease.
  • The report also features the SWOT analysis with analyst insights and key findings of AVR RD 01.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AVR RD 01 Analytical Perspective by DelveInsight

  • In-depth AVR RD 01 Market Assessment

This report provides a detailed market assessment of AVR RD 01 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • AVR RD 01 Clinical Assessment

The report provides the clinical trials information of AVR RD 01 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Fabry Disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence AVR RD 01 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Fabry Disease are giving market competition to AVR RD 01 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of AVR RD 01.
  • Our in-depth analysis of the forecasted sales data of AVR RD 01 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AVR RD 01.

Key Questions:

  • Which company is developing AVR RD 01 along with the phase of the clinical study?
  • What is the technology utilized in the development of AVR RD 01?
  • What is the product type, route of administration and mechanism of action of AVR RD 01?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AVR RD 01 development?
  • What are the key designations that have been granted to AVR RD 01?
  • What is the forecasted market scenario of AVR RD 01?
  • What is the history of AVR RD 01 and what is its future?
  • What is the forecasted sales of AVR RD 01 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to AVR RD 01?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

  • Table 1 AVR RD 01, Description
  • Table 2 AVR RD 01, Clinical Trial Description
  • Table 3 AVR RD 01, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of AVR RD 01
  • Figure 2 Patent Details, AVR RD 01
  • Figure 3 AVR RD 01, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 AVR RD 01, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 AVR RD 01, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 AVR RD 01, Japan Market Size from 2020 to 2030 (in Millions USD)